SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia293 Stable ...
BOSTON & SAN CARLOS, Calif.--(BUSINESS WIRE)--Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced a licensing agreement for its CHO Edge System ...
Synthetic bio company Asimov agreed to collaborate with Cytiva to provide customers with an integrated offering for optimized biologics production. Access includes Asimov’s CHO Edge cell line ...
This partnership provides the industry with cutting-edge options for mammalian-expressed products. OKLAHOMA CITY & MONTHEY, Switzerland--(BUSINESS WIRE)--ExcellGene SA, a leading Swiss biotech service ...
Aragen Biologics launched CHOMax™, a new cell line development and early manufacturing platform that the company says supports an integrated path from DNA to IND-enabling clinical supply for suitable ...
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Privately held CHO Plus, Inc. announced today a project agreement awarded from the Biomedical Advanced Research and Development Authority ...
TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integration technique to streamline clone screening and guarantees expression stability. The platform has achieved ...
The MarketWatch News Department was not involved in the creation of this content. SAN DIEGO, Sept. 15, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO for complex biologics and ...
Join us as we reveal the revolutionary capabilities of Bruker Cellular Analysis' Beacon Optofluidic system. The Beacon platform provides a complete picture of single cell function through real-time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results